Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed By Rituximab in Hairy Cell Leukemia

Trial Profile

Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed By Rituximab in Hairy Cell Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Cladribine (Primary) ; Rituximab (Primary)
  • Indications Hairy cell leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jan 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Jun 2019.
    • 17 Mar 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018 as reported by ClinicalTrials.gov record.
    • 17 Sep 2015 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top